文献速递先天性心脏病外科心外重症与机械循环支持

HeartMate 3 心室辅助装置桥接儿童心脏移植全国结局

National Outcomes of Pediatric Patients Bridged to Heart Transplant With the Heartmate 3 Ventricular Assist Device.
PubMed 文献 · Ann Thorac Surg · 2026-06-03

本研究基于UNOS数据库回顾性分析了美国254例18岁以下接受HeartMate 3(HM3)支持的儿童患者,其中230例(90.6%)成功桥接至移植,中位支持83天,移植后1年生存率96.6%,5年85.8%。先天性心脏病(CHD)与获得性心脏病(AHD)患者移植后1年及3年生存率无显著差异。

要点

  • HM3在较大儿童中桥接移植有效,90.6%成功桥接至移植。
  • 移植后1年生存率96.6%,5年85.8%,透析和卒中发生率低。
  • CHD与AHD患者移植后1年及3年生存率无显著差异。

核心结论

  • HM3是较大儿童患者有效的桥接移植手段,CHD与AHD患者长期结局相当。

研究设计与样本

  • 回顾性队列研究,查询UNOS数据库中截至2024年12月所有18岁以下曾接受HM3支持的患者,共254例。

主要发现

  • 254例中230例(90.6%)成功桥接至移植,10例(3.9%)未用HM3移植,14例(5.5%)未移植并从等待名单移除。
  • 等待名单死亡12例(4.7%)。
  • 230例成功桥接患者中位年龄14.0岁(IQR 12.0-16.0),中位体重56.9 kg(IQR 43.3-75.0),中位支持83.0天(IQR 35.0-184.0)。
  • 左心室辅助装置占206/230(89.6%),双心室辅助装置20/230(8.7%),右心室辅助装置4/230(1.7%)。
  • 移植后透析17/230(7.4%),卒中8/230(3.5%);1年移植后死亡率7/230(3.0%),1年生存率96.6%(95%CI 94.1%-99.1%),5年生存率85.8%(95%CI 78.6%-93.6%)。

关键数值与推荐

  • HM3桥接移植适用于较大儿童患者(中位年龄14.0岁,中位体重56.9 kg)。

临床怎么用

  • 对于较大儿童心力衰竭患者,HM3可作为有效的桥接移植选择,CHD与AHD患者均可获得良好长期生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We evaluated the national outcomes of all pediatric patients bridged-to-transplant with the HeartMate 3 (HM3) (Abbott Corp) and compared the outcomes of those with congenital (CHD) vs acquired (AHD) heart disease. METHODS: The United Network for Organ Sharing (UNOS) database was queried for all patients aged <18 years in the United States ever supported with HM3 and entered into UNOS up to December 2024. Univariable analyses were performed to assess baseline characteristics and posttransplant survival. RESULTS: A total of 254 patients aged <18 years in UNOS have been supported with HM3 in the United States and entered into UNOS up to December 2024, including 230 of 254 (90.6%) successfully bridged-to-transplant with HM3, 10 of 254 (3.9%) transplanted without HM3, and 14 of 245 (5.5%) not transplanted and removed from the waiting list. Overall waitlist mortality was 12 of 254 (4.7%). Of the 230 recipients successfully bridged-to-transplant with HM3, median age at listing and median weight at listing were 14.0 (interquartile range [IQR], 12.0-16.0; range, 7.0-17.0) years and 56.9 (IQR, 43.3-75.0; range, 16.5-141.0) kg, respectively. Median duration of support was 83.0 (IQR, 35.0-184.0) days. Left ventricular assist device (VAD),was the predominant VAD configuration (206 of 230, 89.6%) followed by biventricular assist device (20 of 230, 8.7%) and right VAD (4 of 230, 1.7%). Posttransplant rates of dialysis (17 of 230, 7.4%) and stroke (8 of 230, 3.5%) were low across the cohort. Aggregate 1-year posttransplant mortality was 7 of 230 (3.0), with survival estimates of 96.6% at 1 year (95% CI, 94.1%-99.1%), and 85.8% at 5 years (95% CI, 78.6%-93.6%). CHD patients had longer durations of HM3 support compared with AHD patients (141 [IQR, 59.0-235.0] days vs 76.0 [IQR, 33.0-167.0] days, P = .013). No difference was observed between CHD and AHD in 1-year posttransplant mortality (1 of 39 [2.6%] in CHD and 6 of 191 [3.1%] in AHD, P = .999) nor in 3-year posttransplant survival (90.6% [95% CI, 78.2%-99.9%] in CHD and 90.1% [95% CI, 84.9%-95.5%] in AHD, P = .828). CONCLUSIONS: HM3 is an effective bridge-to-transplant in larger pediatric patients, with equivalent long-term outcomes between CHD and AHD.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Bilgili A, Purlee MS, Shillingford MS, et al. National Outcomes of Pediatric Patients Bridged to Heart Transplant With the Heartmate 3 Ventricular Assist Device. Ann Thorac Surg. 2026. PMID: 42235843. doi:10.1016/j.athoracsur.2026.05.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。